AstraZeneca's Lynparza Successful in Second Ovarian Cancer Phase 3 Study

   By Carlo Martuscelli 
 

AstraZeneca PLC (AZN.LN) said Wednesday that its cancer drug Lynparza has again shown positive results as a treatment for advanced ovarian cancer in a phase 3 study.

Lynparza was being administered as a first-line maintenance therapy in women regardless of BRCA gene mutation status.

The drug had previously met its primary endpoint as a treatment for ovarian cancer in the Solo-1 trial.

According the FTSE 100-listed company, Lynparza combined with olaparib--a standard medication for the disease--was able to prolong the amount of time patients being administered the treatment lived without disease progression or death when compared to those just taking olaparib alone.

Lynparza, which is being developed jointly with Merck & Co. Inc. (MRK), recently yielded positive results in another study as a treatment for prostate cancer. It is the only drug in its class--known as PARP inhibitors--that has shown to be effective in phase 3 trials across ovarian, breast, pancreatic and prostate cancer.

Write to Carlo Martuscelli at [e-mail]

(END) Dow Jones Newswires

August 14, 2019 02:45 ET (06:45 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.